# Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

> **NCT01195649** · — · TERMINATED · sponsor: **Bayer** · enrollment: 11 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT01195649
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12-13
- **Primary completion:** 2012-06-08
- **Final completion:** 2012-08-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195649, "Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01195649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*